請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/102111完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 周文堅 | zh_TW |
| dc.contributor.advisor | Wen-Chien Chou | en |
| dc.contributor.author | 林明恩 | zh_TW |
| dc.contributor.author | Ming-En Lin | en |
| dc.date.accessioned | 2026-03-13T16:31:22Z | - |
| dc.date.available | 2026-03-14 | - |
| dc.date.copyright | 2026-03-13 | - |
| dc.date.issued | 2026 | - |
| dc.date.submitted | 2026-02-05 | - |
| dc.identifier.citation | 1 Döhner H, Weisdorf DJ, Bloomfield CD. Acute Myeloid Leukemia. N Engl J Med 2015; 373: 1136-1152.
2 Roller A, Grossmann V, Bacher U, Poetzinger F, Weissmann S, Nadarajah N et al. Landmark analysis of DNMT3A mutations in hematological malignancies. Leukemia 2013; 27: 1573-1578. 3 Ley TJ, Ding L, Walter MJ, McLellan MD, Lamprecht T, Larson DE et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med 2010; 363: 2424-2433. 4 Hou HA, Kuo YY, Liu CY, Chou WC, Lee MC, Chen CY et al. DNMT3A mutations in acute myeloid leukemia: stability during disease evolution and clinical implications. Blood 2012; 119: 559-568. 5 Lin M-E, Hou H-A, Tsai C-H, Wu S-J, Kuo Y-Y, Tseng M-H et al. Dynamics of DNMT3A mutation and prognostic relevance in patients with primary myelodysplastic syndrome. Clinical Epigenetics 2018; 10: 42. 6 Lee SH, Chiu YC, Li YH, Lin CC, Hou HA, Chou WC et al. High expression of dedicator of cytokinesis 1 (DOCK1) confers poor prognosis in acute myeloid leukemia. Oncotarget 2017; 8: 72250-72259. 7 Zhang G, Zhang J, Yang X, Zhang X, Yang S, Wang J et al. High expression of dedicator of cytokinesis 1 adversely influences the prognosis of acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation. Cancer Manag Res 2019; 11: 3053-3060. 8 Yoshitomi M, Tsujimoto SI, Ikeda J, Kawai T, Ohki K, Hara Y et al. High DOCK1 expression identifies a distinct prognostic subgroup of pediatric acute myeloid leukemia: Results of the Japanese Pediatric Leukemia/Lymphoma Study Group AML-05 trial. Pediatr Blood Cancer 2024; 71: e31151. 9 Laurin M, Côté JF. Insights into the biological functions of Dock family guanine nucleotide exchange factors. Genes Dev 2014; 28: 533-547. 10 Koubek EJ, Santy LC. Actin Up: An Overview of the Rac GEF Dock1/Dock180 and Its Role in Cytoskeleton Rearrangement. Cells 2022; 11. 11 Shimony S, Stahl M, Stone RM. Acute Myeloid Leukemia: 2025 Update on Diagnosis, Risk-Stratification, and Management. American Journal of Hematology 2025; 100: 860-891. 12 Wang J, Wang P, Zhang T, Gao Z, Wang J, Feng M et al. Molecular mechanisms for stemness maintenance of acute myeloid leukemia stem cells. Blood Sci 2019; 1: 77-83. 13 Miraki-Moud F, Anjos-Afonso F, Hodby KA, Griessinger E, Rosignoli G, Lillington D et al. Acute myeloid leukemia does not deplete normal hematopoietic stem cells but induces cytopenias by impeding their differentiation. Proceedings of the National Academy of Sciences of the United States of America 2013; 110: 13576-13581. 14 Rauch PJ, Ellegast JM, Widmer CC, Fritsch K, Goede JS, Valk PJ et al. MPL expression on AML blasts predicts peripheral blood neutropenia and thrombocytopenia. Blood 2016; 128: 2253-2257. 15 Hornick NI, Doron B, Abdelhamed S, Huan J, Harrington CA, Shen R et al. AML suppresses hematopoiesis by releasing exosomes that contain microRNAs targeting c-MYB. Sci Signal 2016; 9: ra88. 16 Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia 2022; 36: 1703-1719. 17 Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood 2022; 140: 1200-1228. 18 Forghieri F, Nasillo V, Paolini A, Bettelli F, Pioli V, Giusti D et al. NPM1-Mutated Myeloid Neoplasms with <20% Blasts: A Really Distinct Clinico-Pathologic Entity? Int J Mol Sci 2020; 21. 19 Patel SS, Ho C, Ptashkin RN, Sadigh S, Bagg A, Geyer JT et al. Clinicopathologic and genetic characterization of nonacute NPM1-mutated myeloid neoplasms. Blood Adv 2019; 3: 1540-1545. 20 Foucar K, Anastasi J. Acute Myeloid Leukemia With Recurrent Cytogenetic Abnormalities. American Journal of Clinical Pathology 2015; 144: 6-18. 21 Taube F, Georgi JA, Kramer M, Stasik S, Middeke JM, Röllig C et al. CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome. Blood 2022; 139: 87-103. 22 Döhner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 2022; 140: 1345-1377. 23 Kantarjian HM, DiNardo CD, Kadia TM, Daver NG, Altman JK, Stein EM et al. Acute myeloid leukemia management and research in 2025. CA Cancer J Clin 2025; 75: 46-67. 24 Shokoohi M, Ghaderi M, Mokarami M, Arian H, Mohammadnabi S, Farokhi A. Targeted and epigenetic therapies for acute myeloid leukemia treatment. Discov Oncol 2025; 16: 1711. 25 Oliva EN, Franek J, Patel D, Zaidi O, Nehme SA, Almeida AM. The Real-World Incidence of Relapse in Acute Myeloid Leukemia (AML): A Systematic Literature Review (SLR). Blood 2018; 132: 5188-5188. 26 Niu J, Peng D, Liu L. Drug Resistance Mechanisms of Acute Myeloid Leukemia Stem Cells. Front Oncol 2022; 12: 896426. 27 Stelmach P, Trumpp A. Leukemic stem cells and therapy resistance in acute myeloid leukemia. Haematologica 2023; 108: 353-366. 28 Zha C, Yang X, Yang J, Zhang Y, Huang R. Immunosuppressive microenvironment in acute myeloid leukemia: overview, therapeutic targets and corresponding strategies. Annals of Hematology 2024; 103: 4883-4899. 29 Guarnera L, Santinelli E, Galossi E, Cristiano A, Fabiani E, Falconi G et al. Microenvironment in acute myeloid leukemia: focus on senescence mechanisms, therapeutic interactions, and future directions. Exp Hematol 2024; 129: 104118. 30 Han X, Liu X, Wan K, Yan H, Zhang M, Liu H et al. The clinical features and outcomes of elderly patients with acute myeloid leukemia: a real word research. Clinical and Experimental Medicine 2025; 25: 27. 31 Kim N, Hahn S, Choi YJ, Cho H, Chung H, Jang JE et al. Comprehensive insights into AML relapse: genetic mutations, clonal evolution, and clinical outcomes. Cancer Cell International 2024; 24: 174. 32 Thol F, Döhner H, Ganser A. How I treat refractory and relapsed acute myeloid leukemia. Blood 2024; 143: 11-20. 33 Abaza Y, Winer ES, Murthy GSG, Shallis RM, Matthews AH, Badar T et al. Clinical outcomes of hypomethylating agents plus Venetoclax as frontline treatment in patients 75 years and older with acute myeloid leukemia: Real-world data from eight US academic centers. American Journal of Hematology 2024; 99: 606-614. 34 Brugnera E, Haney L, Grimsley C, Lu M, Walk SF, Tosello-Trampont AC et al. Unconventional Rac-GEF activity is mediated through the Dock180-ELMO complex. Nature cell biology 2002; 4: 574-582. 35 Meller N, Irani-Tehrani M, Ratnikov BI, Paschal BM, Schwartz MA. The novel Cdc42 guanine nucleotide exchange factor, zizimin1, dimerizes via the Cdc42-binding CZH2 domain. The Journal of biological chemistry 2004; 279: 37470-37476. 36 Hiramoto K, Negishi M, Katoh H. Dock4 is regulated by RhoG and promotes Rac-dependent cell migration. Experimental cell research 2006; 312: 4205-4216. 37 Cote JF, Vuori K. Identification of an evolutionarily conserved superfamily of DOCK180-related proteins with guanine nucleotide exchange activity. Journal of cell science 2002; 115: 4901-4913. 38 Watabe-Uchida M, John KA, Janas JA, Newey SE, Van Aelst L. The Rac activator DOCK7 regulates neuronal polarity through local phosphorylation of stathmin/Op18. Neuron 2006; 51: 727-739. 39 Lin Q, Yang W, Baird D, Feng Q, Cerione RA. Identification of a DOCK180-related guanine nucleotide exchange factor that is capable of mediating a positive feedback activation of Cdc42. The Journal of biological chemistry 2006; 281: 35253-35262. 40 Miyamoto Y, Yamauchi J, Sanbe A, Tanoue A. Dock6, a Dock-C subfamily guanine nucleotide exchanger, has the dual specificity for Rac1 and Cdc42 and regulates neurite outgrowth. Experimental cell research 2007; 313: 791-804. 41 Nishikimi A, Meller N, Uekawa N, Isobe K, Schwartz MA, Maruyama M. Zizimin2: a novel, DOCK180-related Cdc42 guanine nucleotide exchange factor expressed predominantly in lymphocytes. FEBS letters 2005; 579: 1039-1046. 42 Namekata K, Enokido Y, Iwasawa K, Kimura H. MOCA induces membrane spreading by activating Rac1. The Journal of biological chemistry 2004; 279: 14331-14337. 43 Jarzynka MJ, Hu B, Hui KM, Bar-Joseph I, Gu W, Hirose T et al. ELMO1 and Dock180, a bipartite Rac1 guanine nucleotide exchange factor, promote human glioma cell invasion. Cancer research 2007; 67: 7203-7211. 44 Erickson MR, Galletta BJ, Abmayr SM. Drosophila myoblast city encodes a conserved protein that is essential for myoblast fusion, dorsal closure, and cytoskeletal organization. J Cell Biol 1997; 138: 589-603. 45 Wu YC, Horvitz HR. C. elegans phagocytosis and cell-migration protein CED-5 is similar to human DOCK180. Nature 1998; 392: 501-504. 46 Grimsley CM, Kinchen JM, Tosello-Trampont AC, Brugnera E, Haney LB, Lu M et al. Dock180 and ELMO1 proteins cooperate to promote evolutionarily conserved Rac-dependent cell migration. The Journal of biological chemistry 2004; 279: 6087-6097. 47 Cote JF, Vuori K. GEF what? Dock180 and related proteins help Rac to polarize cells in new ways. Trends in cell biology 2007; 17: 383-393. 48 Capala ME, Vellenga E, Schuringa JJ. ELMO1 is upregulated in AML CD34+ stem/progenitor cells, mediates chemotaxis and predicts poor prognosis in normal karyotype AML. PloS one 2014; 9: e111568. 49 Gadea G, Blangy A. Dock-family exchange factors in cell migration and disease. European journal of cell biology 2014; 93: 466-477. 50 Nishikimi A, Kukimoto-Niino M, Yokoyama S, Fukui Y. Immune regulatory functions of DOCK family proteins in health and disease. Experimental cell research 2013; 319: 2343-2349. 51 Sakai Y, Tanaka Y, Yanagihara T, Watanabe M, Duan X, Terasawa M et al. The Rac activator DOCK2 regulates natural killer cell-mediated cytotoxicity in mice through the lytic synapse formation. Blood 2013; 122: 386-393. 52 Wu M, Hamaker M, Li L, Small D, Duffield AS. DOCK2 interacts with FLT3 and modulates the survival of FLT3-expressing leukemia cells. Leukemia 2017; 31: 688-696. 53 Hasan MK, Yu J, Widhopf GF, 2nd, Rassenti LZ, Chen L, Shen Z et al. Wnt5a induces ROR1 to recruit DOCK2 to activate Rac1/2 in chronic lymphocytic leukemia. Blood 2018; 132: 170-178. 54 Chen Q, Peto CA, Shelton GD, Mizisin A, Sawchenko PE, Schubert D. Loss of modifier of cell adhesion reveals a pathway leading to axonal degeneration. The Journal of neuroscience : the official journal of the Society for Neuroscience 2009; 29: 118-130. 55 Tachi N, Hashimoto Y, Matsuoka M. MOCA is an integrator of the neuronal death signals that are activated by familial Alzheimer's disease-related mutants of amyloid beta precursor protein and presenilins. The Biochemical journal 2012; 442: 413-422. 56 Sundaravel S, Duggan R, Bhagat T, Ebenezer DL, Liu H, Yu Y et al. Reduced DOCK4 expression leads to erythroid dysplasia in myelodysplastic syndromes. Proceedings of the National Academy of Sciences of the United States of America 2015; 112: E6359-6368. 57 Kuo KT, Guan B, Feng Y, Mao TL, Chen X, Jinawath N et al. Analysis of DNA copy number alterations in ovarian serous tumors identifies new molecular genetic changes in low-grade and high-grade carcinomas. Cancer research 2009; 69: 4036-4042. 58 Nestorowa S, Hamey FK, Pijuan Sala B, Diamanti E, Shepherd M, Laurenti E et al. A single-cell resolution map of mouse hematopoietic stem and progenitor cell differentiation. Blood 2016; 128: e20-31. 59 Dahlin JS, Hamey FK, Pijuan-Sala B, Shepherd M, Lau WWY, Nestorowa S et al. A single-cell hematopoietic landscape resolves 8 lineage trajectories and defects in Kit mutant mice. Blood 2018; 131: e1-e11. 60 Kitamura T, Tange T, Terasawa T, Chiba S, Kuwaki T, Miyagawa K et al. Establishment and characterization of a unique human cell line that proliferates dependently on GM-CSF, IL-3, or erythropoietin. Journal of Cellular Physiology 1989; 140: 323-334. 61 Sugimoto K, Toyoshima H, Sakai R, Miyagawa K, Hagiwara K, Ishikawa F et al. Frequent mutations in the p53 gene in human myeloid leukemia cell lines. Blood 1992; 79: 2378-2383. 62 Quentmeier H, Pommerenke C, Dirks WG, Eberth S, Koeppel M, MacLeod RAF et al. The LL-100 panel: 100 cell lines for blood cancer studies. Scientific Reports 2019; 9: 8218. 63 Cheng T, Rodrigues N, Shen H, Yang Y, Dombkowski D, Sykes M et al. Hematopoietic stem cell quiescence maintained by p21cip1/waf1. Science 2000; 287: 1804-1808. 64 He S, Roberts PJ, Sorrentino JA, Bisi JE, Storrie-White H, Tiessen RG et al. Transient CDK4/6 inhibition protects hematopoietic stem cells from chemotherapy-induced exhaustion. Science translational medicine 2017; 9. 65 Hsu Y-C, Chen T-C, Lin C-C, Yuan C-T, Hsu C-L, Hou H-A et al. Phf6-null hematopoietic stem cells have enhanced self-renewal capacity and oncogenic potentials. Blood Advances 2019; 3: 2355-2367. 66 Wang Y-H, Hou H-A, Lin C-C, Kuo Y-Y, Yao C-Y, Hsu C-L et al. A CIBERSORTx-based immune cell scoring system could independently predict the prognosis of patients with myelodysplastic syndromes. Blood Advances 2021; 5: 4535-4548. 67 Chen Y, Lun AT, Smyth GK. From reads to genes to pathways: differential expression analysis of RNA-Seq experiments using Rsubread and the edgeR quasi-likelihood pipeline. F1000Res 2016; 5: 1438. 68 Butler A, Hoffman P, Smibert P, Papalexi E, Satija R. Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat Biotechnol 2018; 36: 411-420. 69 Chen TC, Yao CY, Chen YR, Yuan CT, Lin CC, Hsu YC et al. Oncogenesis induced by combined Phf6 and Idh2 mutations through increased oncometabolites and impaired DNA repair. Oncogene 2022; 41: 1576-1588. 70 Wu T, Hu E, Xu S, Chen M, Guo P, Dai Z et al. clusterProfiler 4.0: A universal enrichment tool for interpreting omics data. Innovation (Camb) 2021; 2: 100141. 71 Chen EY, Tan CM, Kou Y, Duan Q, Wang Z, Meirelles GV et al. Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinformatics 2013; 14: 128. 72 Kuleshov MV, Jones MR, Rouillard AD, Fernandez NF, Duan Q, Wang Z et al. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res 2016; 44: W90-97. 73 Xie Z, Bailey A, Kuleshov MV, Clarke DJB, Evangelista JE, Jenkins SL et al. Gene Set Knowledge Discovery with Enrichr. Curr Protoc 2021; 1: e90. 74 Carella C, Bonten J, Sirma S, Kranenburg TA, Terranova S, Klein-Geltink R et al. MN1 overexpression is an important step in the development of inv(16) AML. Leukemia 2007; 21: 1679-1690. 75 Heuser M, Argiropoulos B, Kuchenbauer F, Yung E, Piper J, Fung S et al. MN1 overexpression induces acute myeloid leukemia in mice and predicts ATRA resistance in patients with AML. Blood 2007; 110: 1639-1647. 76 Kandilci A, Grosveld GC. Reintroduction of CEBPA in MN1-overexpressing hematopoietic cells prevents their hyperproliferation and restores myeloid differentiation. Blood 2009; 114: 1596-1606. 77 Li D, Li T, Shang Z, Zhao L, Xu Q, Tan J et al. Combined inhibition of Notch and FLT3 produces synergistic cytotoxic effects in FLT3/ITD(+) acute myeloid leukemia. Signal Transduct Target Ther 2020; 5: 21. 78 Takam Kamga P, Dal Collo G, Resci F, Bazzoni R, Mercuri A, Quaglia FM et al. Notch Signaling Molecules as Prognostic Biomarkers for Acute Myeloid Leukemia. Cancers (Basel) 2019; 11. 79 Kode A, Manavalan JS, Mosialou I, Bhagat G, Rathinam CV, Luo N et al. Leukaemogenesis induced by an activating beta-catenin mutation in osteoblasts. Nature 2014; 506: 240-244. 80 Kang YA, Pietras EM, Passegue E. Deregulated Notch and Wnt signaling activates early-stage myeloid regeneration pathways in leukemia. J Exp Med 2020; 217. 81 Kannan S, Sutphin RM, Hall MG, Golfman LS, Fang W, Nolo RM et al. Notch activation inhibits AML growth and survival: a potential therapeutic approach. J Exp Med 2013; 210: 321-337. 82 Ma Z, Xu J, Wu L, Wang J, Lin Q, Chowdhury FA et al. Hes1 deficiency causes hematopoietic stem cell exhaustion. STEM CELLS 2020; 38: 756-768. 83 Wang J, Zhu M, Zhu J, Li J, Zhu X, Wang K et al. HES1 promotes aerobic glycolysis and cancer progression of colorectal cancer via IGF2BP2-mediated GLUT1 m6A modification. Cell Death Discov 2023; 9: 411. 84 Ku SY, Wang Y, Garcia MM, Yamada Y, Mizuno K, Long MD et al. Notch signaling suppresses neuroendocrine differentiation and alters the immune microenvironment in advanced prostate cancer. J Clin Invest 2024; 134. 85 Nakahara F, Kitaura J, Uchida T, Nishida C, Togami K, Inoue D et al. Hes1 promotes blast crisis in chronic myelogenous leukemia through MMP-9 upregulation in leukemic cells. Blood 2014; 123: 3932-3942. 86 Meng S, Su Z, Liu Z, Wang N, Wang Z. Rac1 contributes to cerebral ischemia reperfusion-induced injury in mice by regulation of Notch2. Neuroscience 2015; 306: 100-114. 87 Meurette O, Stylianou S, Rock R, Collu GM, Gilmore AP, Brennan K. Notch activation induces Akt signaling via an autocrine loop to prevent apoptosis in breast epithelial cells. Cancer research 2009; 69: 5015-5022. 88 Kohlhaas V, Blakemore SJ, Al-Maarri M, Nickel N, Pal M, Roth A et al. Active Akt signaling triggers CLL toward Richter transformation via overactivation of Notch1. Blood 2021; 137: 646-660. 89 Espinosa L, Inglés-Esteve J, Aguilera C, Bigas A. Phosphorylation by glycogen synthase kinase-3 beta down-regulates Notch activity, a link for Notch and Wnt pathways. The Journal of biological chemistry 2003; 278: 32227-32235. 90 Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 1995; 378: 785-789. 91 Guo J, Jiang X, Lian J, Li H, Zhang F, Xie J et al. Evaluation of the effect of GSK-3β on liver cancer based on the PI3K/AKT pathway. Front Cell Dev Biol 2024; 12: 1431423. 92 Meyer AE, Stelloh C, Pulakanti K, Burns R, Fisher JB, Heimbruch KE et al. Combinatorial genetics reveals the Dock1-Rac2 axis as a potential target for the treatment of NPM1;Cohesin mutated AML. Leukemia 2022; 36: 2032-2041. 93 Yang X, Wang Y, Pang S, Li X, Wang P, Ma R et al. LINC00665 promotes the progression of acute myeloid leukemia by regulating the miR-4458/DOCK1 pathway. Sci Rep 2021; 11: 5009. 94 Koubek EJ, Santy LC. Actin Up: An Overview of the Rac GEF Dock1/Dock180 and Its Role in Cytoskeleton Rearrangement. Cells 2022; 11: 3565. 95 Feng H, Hu B, Jarzynka MJ, Li Y, Keezer S, Johns TG et al. Phosphorylation of dedicator of cytokinesis 1 (Dock180) at tyrosine residue Y722 by Src family kinases mediates EGFRvIII-driven glioblastoma tumorigenesis. Proceedings of the National Academy of Sciences of the United States of America 2012; 109: 3018-3023. 96 Choe G, Horvath S, Cloughesy TF, Crosby K, Seligson D, Palotie A et al. Analysis of the phosphatidylinositol 3'-kinase signaling pathway in glioblastoma patients in vivo. Cancer research 2003; 63: 2742-2746. 97 Fritsch R, de Krijger I, Fritsch K, George R, Reason B, Kumar MS et al. RAS and RHO families of GTPases directly regulate distinct phosphoinositide 3-kinase isoforms. Cell 2013; 153: 1050-1063. 98 Feng H, Hu B, Liu KW, Li Y, Lu X, Cheng T et al. Activation of Rac1 by Src-dependent phosphorylation of Dock180(Y1811) mediates PDGFRα-stimulated glioma tumorigenesis in mice and humans. J Clin Invest 2011; 121: 4670-4684. 99 Kaneto N, Yokoyama S, Hayakawa Y, Kato S, Sakurai H, Saiki I. RAC1 inhibition as a therapeutic target for gefitinib-resistant non-small-cell lung cancer. Cancer Sci 2014; 105: 788-794. 100 Park S, Chapuis N, Tamburini J, Bardet V, Cornillet-Lefebvre P, Willems L et al. Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia. Haematologica 2010; 95: 819-828. 101 Kornblau SM, Womble M, Qiu YH, Jackson CE, Chen W, Konopleva M et al. Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia. Blood 2006; 108: 2358-2365. 102 Grandage VL, Gale RE, Linch DC, Khwaja A. PI3-kinase/Akt is constitutively active in primary acute myeloid leukaemia cells and regulates survival and chemoresistance via NF-kappaB, Mapkinase and p53 pathways. Leukemia 2005; 19: 586-594. 103 Darici S, Alkhaldi H, Horne G, Jørgensen HG, Marmiroli S, Huang X. Targeting PI3K/Akt/mTOR in AML: Rationale and Clinical Evidence. J Clin Med 2020; 9. | - |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/102111 | - |
| dc.description.abstract | 此研究探討DOCK1基因在血液生成中的角色及其於急性骨髓性白血病的臨床與生物意義。DOCK家族的基因轉錄並轉譯一群作用於Rho鳥苷三磷酸酶之演化上保守的鳥糞嘌呤核苷酸交換因子,與多種生理程序的調節有關。DOCK1基因屬於DOCK家族基因的一員,所轉錄並轉譯的DOCK1蛋白已知與乳癌及神經膠母細胞瘤的轉移和侵襲性有關。雖然某些DOCK家族的蛋白可能調控血液生成,而它們的異常可能與白血病生成有關,但是它們在急性骨髓性白血病實際的角色仍不清楚。先前一項研究發現DOCK1基因表現量在急性骨髓性白血病患有獨立的預後意義,且其在急性骨髓性白血病預後評估方面表現更佳,預測能力優於多個已發表的基因標誌。DOCK1基因主要在造血幹細胞表現,且基因富集分析顯示與造血幹細胞及白血病幹細胞相關的基因在DOCK1基因表現高的病患表現也較高,因此我們假設DOCK1基因藉由對細胞幹性、增殖、運動與趨化性的調節而影響白血病病患的預後。我們檢測了多個急性骨髓性白血病細胞株中DOCK1基因的表現量,發現TF1細胞株和HEL92.1.7細胞株(以下簡稱HEL細胞)有較高的DOCK1基因表現。這兩種細胞株在使用CRISPR-Cas9系統剔除DOCK1基因後存活率都降低,而且HEL細胞的凋亡率顯著升高。使用shRNA降低HEL細胞以及DOCK1低表達之HL-60細胞的DOCK1基因表現後也獲得了一致的結果。在異種移植模型中,DOCK1基因表現受抑制的HEL細胞在受體小鼠中移植成功的速度較慢,而接受DOCK1基因表現受抑制的HEL細胞移植的小鼠比接受相同數量對照細胞移植的小鼠存活期顯著延長。小鼠骨髓細胞在剔除造血細胞之Dock1基因後,在5-FU注射試驗與競爭性移植試驗中呈現的造血能力較未剔除Dock1基因之細胞差。藉由反轉錄病毒轉導MN1基因,我們發現剔除Dock1基因的小鼠骨髓細胞在MN1基因過度表現下的增殖與遷移能力較過度表現MN1基因之Dock1基因野生型骨髓細胞差。接受致死劑量輻射照射的小鼠移植了這些骨髓細胞後,其存活期明顯長於接受相同數量之過度表現MN1基因的Dock1基因野生型骨髓細胞移植的小鼠,且血液採樣顯示接受剔除Dock1基因之骨髓細胞移植的小鼠血液中MN1基因過度表現之細胞所佔的百分比亦較低。這些結果顯示DOCK1基因對造血細胞和白血病細胞存活與增殖的重要性。轉錄組分析和免疫化學染色證明DOCK1基因表現與Notch訊號上調存在關聯,而細胞株實驗則顯示DOCK1基因表現與Notch訊號上調之間有因果關係。對MN1基因過度表現的Dock1基因條件性剔除小鼠和Dock1基因野生型小鼠骨髓細胞進行單細胞定序分析,發現一群獨特的細胞群集幾乎只存在於Dock1基因野生型小鼠的樣本中。此群集的幹細胞標誌訊號上調,同時,身為Notch訊號傳導主要目標的Hes1基因表現也增加。這些研究結果突顯了DOCK1基因在急性骨髓性白血病中臨床與致病機轉上的重要性,以及其與Notch訊號傳導的關係,顯示其是潛在的治療標的。 | zh_TW |
| dc.description.abstract | In this study, we focus on the roles of Dedicator of cytokinesis 1 (DOCK1) gene in hematopoiesis and its clinical and biological significance in acute myeloid leukemia (AML). DOCK family genes encode evolutionarily conserved guanine nucleotide exchange factors (GEFs) for Rho GTPases involving in the regulation of various physiological processes. The DOCK1 gene, a member of DOCK family genes, encodes the DOCK1 protein, which has been known to be involved in the migration and invasion of breast cancer cells and glioblastoma cells. Although some of the DOCK family proteins possibly regulate hematopoiesis, and their deregulation might contribute to leukemogenesis, little is known about their roles in AML. A previous study revealed that the mRNA levels of DOCK1 gene have independent prognostic significance in AML cohorts, and its predictive power outperformed several published gene signatures in AML prognostication. In addition, DOCK1 expression appears to be exclusively upregulated in hematopoietic stem cells, and Gene Set Enrichment Analysis (GSEA) also showed concordant upregulation of hematopoietic stem cell- and leukemic stem cell-associated genes in patients with higher DOCK1 expression in the analysis, implying its role in stem cell biology. Therefore, we hypothesize that the DOCK1 influences the prognosis of AML possibly through its correlation with stemness, cell proliferation, motility and chemotaxis. We tested the expression of DOCK1 in various myeloid leukemia cell lines and found TF1 and HEL 92.1.7 (shortened as HEL) cell lines exhibit higher DOCK1 expression. We knocked out the DOCK1 gene in these two cell lines using the CRISPR-Cas9 system. This resulted in decreased viability in both cell lines, with HEL cells showing a higher apoptosis rate after DOCK1 knockout. Consistent findings were obtained following shRNA-mediated DOCK1 knockdown in both HEL cells and DOCK1-low-expressing HL-60 cells. In a xenograft model, the DOCK1-knockdown HEL cells exhibited delayed engraftment in the recipient mice, and the mice transplanted with DOCK1-knockdown HEL cells showed a significantly prolonged survival than those transplanted with the same number of control cells. In the Dock1-conditional knockout (Dock1-cKO) mouse model, the bone marrow cells of Dock1-cKO mice tended to have worse regeneration ability than those of Dock1-wild type (Dock1-WT) mice in the 5-fluorouracil survival assays. In the competitive repopulating units assay, recipient mice transplanted with the bone marrow cells from Dock1-cKO mice showed a significantly inferior capacity to reconstitute their hematopoietic system compared with those transplanted with the bone marrow cells from gender- and age-matched Dock1-WT mice. By means of retroviral transduction, we demonstrated that MN1-overexpressing bone marrow cells from Dock1-cKO mice tend to have a reduced ability to maintain populations, aggregate, and migrate. The lethally irradiated mice transplanted with bone marrow cells from MN1-overexpressing Dock1-cKO mice had a significantly longer median overall survival than those transplanted with the same number of bone marrow cells from MN1-overexpressing Dock1-WT mice, with blood sampling revealing a lower percentage of circulating MN1-overexpressing cells in the recipient mice. These findings support the importance of DOCK1 expression in the survival and proliferation of hematopoietic stem cells and leukemia cells. Transcriptome analyses and immunochemistry stain demonstrated an association between DOCK1 expression and upregulated Notch signaling, and the causal relationship was supported by cell line experiments. Single-cell sequencing analysis of MN1-overexpressing bone marrow cells from Dock1-cKO and Dock1-WT mice identified a unique cell cluster that was present almost exclusively in the Dock1 wildtype background. This cluster was defined by the concomitant upregulation of both a stem cell signature and Hes1 expression, a primary effector of Notch signaling. These findings highlight the clinical and pathogenic significance of DOCK1 in AML and its relationship with Notch signaling, thereby supporting its potential as a therapeutic target. | en |
| dc.description.provenance | Submitted by admin ntu (admin@lib.ntu.edu.tw) on 2026-03-13T16:31:22Z No. of bitstreams: 0 | en |
| dc.description.provenance | Made available in DSpace on 2026-03-13T16:31:22Z (GMT). No. of bitstreams: 0 | en |
| dc.description.tableofcontents | 口試委員會審定書 i
誌謝 ii 中文摘要 iii 英文摘要 v 第一章 緒論(Introduction) 1 1.1 前言 1 1.2文獻回顧 2 1.2.1 急性骨髓性白血病簡介 2 1.2.2 急性骨髓性白血病治療的困境 4 1.2.3 DOCK家族蛋白簡介 6 1.2.4 DOCK1基因在急性骨髓性白血病的角色 7 1.3研究的問題及其重要性 8 第二章 研究材料與方法(Materials and Methods) 10 2.1 研究樣本族群 10 2.2 染色體分析 10 2.3 分子分析 10 2.4細胞培養 11 2.5 以CRISPR–Cas9技術進行DOCK1基因剔除 12 2.6 以siRNA抑制DOCK1基因表現 12 2.7 以shRNA抑制DOCK1基因表現 13 2.8 細胞活率分析 13 2.9 細胞株衍生異種移植小鼠模式 14 2.10 5-氟尿嘧啶(5-FU)存活分析 14 2.11建立Dock1基因條件式剔除小鼠模式 14 2.12小鼠骨髓移植與競爭性再造單位分析 15 2.13反轉錄病毒MN1基因轉導 16 2.14 Rac1蛋白活化分析 16 2.15 Transwell細胞遷移實驗 17 2.16用於免疫轉漬、免疫組織化學染色與流式分析的抗體 17 2.17螢光活化細胞分選(FACS)分析與細胞分選 18 2.18基因庫製備、RNA定序與基因表現分析 19 2.19單細胞RNA定序分析 19 2.20 10×Genomics單細胞RNA定序資料的處理與分析 20 2.21統計分析 21 第三章 結果(Results) 22 3.1 DOCK1基因高表現與特定臨床特徵相關,並可預測急性骨髓性白血病患者的不良預後 22 3.2 DOCK1基因表現量在不同的基因突變狀態下對急性骨髓性白血病患者預後的影響 23 3.3減少DOCK1基因表現可降低HEL與TF1細胞的存活能力,並在異種移植模型中延長受體小鼠的存活期 24 3.4 接受DOCK1基因表現受抑制的HEL細胞移植的小鼠存活率顯著提高 25 3.5 Dock1基因條件式剔除小鼠呈現不明顯的造血相關表型變化 25 3.6 5-氟尿嘧啶(5-FU)存活實驗顯示Dock1基因條件式剔除小鼠的造血前驅細胞的再生能力有較差的傾向25 3.7競爭性再造單位分析(CRU assay)顯示Dock1基因條件式剔除小鼠呈現較差的造血系統重建能力 26 3.8 Dock1基因剔除可延長罹患MN1基因過度表現所誘發之急性骨髓性白血病之小鼠的存活期 26 3.9 Dock1基因條件式剔除小鼠的骨髓細胞在MN1基因過度表現後呈現較低的RAC1蛋白活性 27 3.10 MN1基因過度表現的Dock1基因條件式剔除小鼠骨髓細胞呈現較低的遷移能力傾向 27 3.11 DOCK1基因下調會降低Notch訊號傳導途徑的活性 27 3.12第10對染色體異常與DOCK1、NOTCH2、或HES1基因表現量並未發現顯著關聯 29 3.13單細胞RNA定序顯示Dock1基因條件式剔除小鼠的細胞組成發生改變 29 3.14 DOCK1基因剔除會削弱MN1基因過度表現所誘導之急性骨髓性白血病的白血病幹細胞特徵 30 第四章 討論(Discussion) 31 第五章 展望(Perspectives) 36 參考文獻 (Reference) 82 附錄 (Appendix) 91 | - |
| dc.language.iso | zh_TW | - |
| dc.subject | DOCK1基因 | - |
| dc.subject | 急性骨髓性白血病 | - |
| dc.subject | Notch訊號 | - |
| dc.subject | 白血病生成 | - |
| dc.subject | 預後 | - |
| dc.subject | DOCK1 | - |
| dc.subject | acute myeloid leukemia | - |
| dc.subject | Notch | - |
| dc.subject | leukemogenesis | - |
| dc.subject | prognosis | - |
| dc.title | 抑制DOCK1基因藉由減少Notch訊息傳遞而抑制白血病生成 | zh_TW |
| dc.title | Down-regulation of DOCK1 Gene Suppresses Leukemogenesis by Inhibiting Notch Signaling Pathway | en |
| dc.type | Thesis | - |
| dc.date.schoolyear | 114-1 | - |
| dc.description.degree | 博士 | - |
| dc.contributor.coadvisor | 陳培哲 | zh_TW |
| dc.contributor.coadvisor | Pei-Jer Chen | en |
| dc.contributor.oralexamcommittee | 田蕙芬;侯信安;林亮音;張原翊 | zh_TW |
| dc.contributor.oralexamcommittee | Hwei-Fang Tien;Hsin-An Hou;Liang-In Lin;Yuan-I Chang | en |
| dc.subject.keyword | DOCK1基因,急性骨髓性白血病Notch訊號白血病生成預後 | zh_TW |
| dc.subject.keyword | DOCK1,acute myeloid leukemiaNotchleukemogenesisprognosis | en |
| dc.relation.page | 93 | - |
| dc.identifier.doi | 10.6342/NTU202600667 | - |
| dc.rights.note | 同意授權(限校園內公開) | - |
| dc.date.accepted | 2026-02-06 | - |
| dc.contributor.author-college | 醫學院 | - |
| dc.contributor.author-dept | 臨床醫學研究所 | - |
| dc.date.embargo-lift | 2031-02-03 | - |
| 顯示於系所單位: | 臨床醫學研究所 | |
文件中的檔案:
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-114-1.pdf 未授權公開取用 | 6.46 MB | Adobe PDF | 檢視/開啟 |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。
